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Abstract: The current drug R&D pipeline for most
neglected diseases remains weak, and unlikely to support
registration of novel drug classes that meet desired target
product profiles in the short term. This calls for sustained
investment as well as greater emphasis in the risky
upstream drug discovery. Access to technologies, resourc-
es, and strong management as well as clear compound
progression criteria are factors in the successful imple-
mentation of any collaborative drug discovery effort. We
discuss how some of these factors have impacted drug
discovery for tropical diseases within the past four
decades, and highlight new opportunities and challenges
through the virtual North–South drug discovery network
as well as the rationale for greater participation of
institutions in developing countries in product innovation.
A set of criteria designed to facilitate compound
progression from screening hits to drug candidate
selection is presented to guide ongoing efforts.
Introduction
The discovery of novel drug leads with the potential to become
usable medicines is an important component of the drug
innovation cycle, but remains a major obstacle in the development
of new drugs for infectious tropical diseases [1]. Historically, this
innovation cycle starts with basic research followed by the
translation of this research into product leads, their further
development, and associated regulation, commercialization, and
ultimate health impact [1,2]. The process is long (typically 10 to 15
years), expensive (costing between US$500 and US$800 million
according to pharmaceutical industry estimates), and technically
challenging [3–5]. It should be mentioned that the cost identified
above includes cost of failed projects, and the actual figure for
neglected diseases will probably be significantly less.
Ideally, the interfaces between the various processes are well
resourced and managed to ensure continuous availability of health
products. Unfortunately, product research and development (R&D)
and access is skewed in favour of ailments that are commercially
attractive, while those diseases that disproportionately affect poor
populationsindevelopingcountriesareneglected.Consequently,an
estimated 1 billion people, one in six of the world’s population,
currently suffer from neglected tropical diseases, mostly in
developing countries [6]. The afflicted populations are poor and
commercial incentives to enable investment in the risky product
R&Dareweak[3,7].Thefew available drugshaveproblemsrelated
to their cost, safety, stability, and increasingly, the threat of
resistance that may limit their utility.
Some of the neglected diseases include malaria, trypanosomiasis,
leishmaniasis, schistosomiasis, filariasis, and onchocerciasis. Malaria
is a major health problem with over 1 million deaths occurring
mainly in children and pregnant women in sub-Saharan Africa
[8,9]. New and affordable antimalarial drugs that are effective
against resistant parasites and can be safely administered to children
and pregnant women are urgently needed [3,10]. Even for malaria,
which has probably had significant investment, the drugs expected
from the existing R&D portfolio in the next few years are a
combination of old drugs that are mostly reliant on artemisinins.
Going by the industrial assessment of attrition, the number of
projects in the pre-clinical phase of R&D is too small to guarantee
success. Recent reports of artemisinin resistance in Asia [11] means
that emphasis has to be placed on the discovery of novel entities to
support the medium to long-term needs of malaria control as well as
possible elimination and eradication. The ongoing discussion on
malaria eradication requires major technical and financial invest-
ment today to support the discovery and development of the tools
needed for eradication beyond the next 15 years.
Tuberculosis (TB) therapy is made complex by the emergence
of drug-resistant strains, and the long courses of treatment [12].
The treatment of human African trypanosomiasis (HAT) depends
on drugs that are very toxic and requires intravenous administra-
tion. New drugs that are effective for both the early- and late-stage
disease and have a greater ease of administration are highly
desirable [13]. Therapy for Chagas disease is limited to nifurtimox
and benznidazole, for which toxicity is dose-limiting [14].
Miltefosine and paromomycin have recently been approved for
visceral leishmaniasis, but drugs for cutaneous disease remain
toxic, difficult to deliver, and of marginal efficacy [15]. Treatment
of diseases caused by parasitic worms (schistosomiasis, lymphatic
filariasis, onchocerciasis) is dependent on a few drugs, many of
which are suboptimal [16,17]. A macrofilaricidal (adult worm-
killing) drug is desperately needed for onchocerciasis and
lymphatic filariasis control, as the drugs now in use require
treatment throughout the 10- year lifespan of adult worms [18].
Moreover, drug resistance is now widespread in worms that affect
livestock, and a similar emergence of resistance in human
populations would severely hamper control efforts [19,20]. There
are also efforts focused on developing drugs including better
antibiotic treatment regimens that can kill the Wolbachia
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The past 10 years have witnessed a new emphasis on the
promotion of innovation and investment in R&D for some of these
diseases, which are largely supported with new funding from
governments as well as philanthropic agencies, notably the Bill &
Melinda Gates Foundation and the Wellcome Trust [3,21–25].
Despite these developments, gaps still exist in the product supply
chain for nearly all diseases that disproportionately affect the
developing world. Recent analysis undertaken by some agencies,
including the World Health Organization (WHO) Special
Programme for Tropical Disease Research (TDR), as well as the
BIO Ventures for Global Health [26], have identified critical gaps
in the R&D process for some of these diseases, covering the
following areas: a) translation of basic research to product leads to
feed the development pipeline, b) product development for the
most neglected diseases including the helminth infections, and c)
implementation research or research to inform access and changes
in drug policy.
With regards to translational research for lead discovery and
development, we previously described an innovative drug
discovery platform for infectious diseases of poverty that involves
coordinated networks and partnerships with industry and
academia in both the developed and developing countries, and
how the networks might be scaled up to achieve a robust pipeline
of new products for the neglected diseases [1,27].
In this paper, we discuss advances and gaps in drug discovery
for tropical diseases in the past few decades as well as factors that
have contributed to recent progress in drug discovery for these
diseases. Specific examples and lessons are drawn from the
coordinated drug discovery network for multiple diseases [1]. A set
of criteria designed to facilitate compound progression from
screening to hit-to-lead and drug candidate selection for these
diseases is shared with the hope that it will be useful for the
broader discovery community for neglected diseases.
Evolution of Drug Discovery for Neglected
Diseases
The impetus for the development of some of the current drugs
against tropical diseases was largely motivated by the needs of
colonialism during the early 20th century [28], by wars in disease-
endemic areas, and by animal health needs [29,30]. The launch of
the TDR in 1976 coincided with the time when pharmaceutical
companies began to withdraw from the discovery and develop-
ment of drugs for tropical diseases. By the end of the 20th century
this withdrawal was almost complete [31]. The lack of commercial
incentives to support the increasing cost of R&D for drugs against
tropical diseases, coupled with the increasing stringent regulatory
requirements, are sometimes cited as reasons for this withdrawal.
This development prompted TDR’s involvement in product
development right from its inception through collaboration with
R&D-based pharmaceutical companies to ensure that candidate
drugs already in development are not shelved. Some of the success
stories through those collaborations are well documented, for
example with Merck in early 1980s over ivermectin for
onchocerciasis, and with Bayer in the late 1970s over the
development of praziquantel for schistosomiasis [31,32].
During the 1980s, it became clear that the prospects of new
chemical entities entering the development pipeline for tropical
diseases were bleak. The high attrition rate also meant that the few
remaining drug discovery programmes that continued within the
pharmaceutical industry had limited chance of becoming registered
products. Thus, this led to an increased focus on testing compounds
already in development in companies for other therapeutic areas for
potential utility in tropical diseases. Funding support from TDR
enabled compound screening against tropical disease pathogens to
be performed in public institutions such as the London School of
Hygiene and Tropical Medicine and the Swiss Tropical Institute, as
well as at Janssen Pharmaceuticals Belgium in 1993 and later at
Tibotec Belgium. This approach markedly reduced discovery costs
given the free access to compounds (meant for other purposes)
provided by industry. The success achieved between 1985 and 1995
through this approach included the investigation of a potential
treatment for visceral leishmaniasis and African sleeping sickness
that resulted in the registration of miltefosine through a collabora-
tion with Zentaris, and eflornithine through a collaboration with
Aventis for those diseases, respectively [29,33]. Both drugs were
originally developed as anti-cancer agents. This piggy-backing or
therapeutic switching had the potential of delivering new drugs
more quickly and at lower costs since much of the development
work had already been done [34]. However, many believe that the
full power of innovation cannot be realized for tropical diseases
through this approach.
Between 1995 and 2004, TDR expanded its screening activities
to introduce the concept of a screening network for various
tropical diseases with the added benefit that experiences, reagents,
and standard operating procedures (SOPs) are shared among the
partners. The activity further evolved to include the testing of
compounds sourced from academic laboratories and commercially
purchased compounds. This approach resulted in the evaluation of
peroxides from different laboratories, including the University of
Mississippi, the Universite Laval Montreal, and the University of
Nebraska. Although TDR did not have the medicinal chemistry
and drug metabolism and pharmacokinetics (DMPK) resources at
that time to take forward promising hits and leads, it should be
noted that some of the identified hits or leads helped some of the
public private partnerships (PPPs) that emerged in the late 1990s
and early 2000s such as Medicines for Malaria Venture (MMV)
and Drugs for Neglected Diseases Initiative (DNDi) to rapidly
identify and initiate lead optimization [3,35,36]. One example of
such a lead optimization program is the Ozonide project
supported by MMV that entered clinical development for malaria
[37]. Some of these PPPs have realized the need to invest in the
more risky early lead identification and are now extending their
operations into this field.
Within the same period, several academic and public centres of
excellence have emerged to support drug discovery for neglected
diseases. For example, the Wellcome Trust drug discovery unit at
the University of Dundee focuses on early stage drug discovery for
HAT; the Sandler Foundation drug discovery facility at the
University of California in San Francisco focuses on early drug
discovery for Chagas disease, schistosomiasis, and malaria; and the
Harvard/Broad Institute focuses on malaria. Prior to the
establishment of these centres, the Central Drug Research Institute
in Lucknow, India, and the Walter Reed Army Research Institute
were also engaged in R&D for tropical diseases. It should also be
noted that several institutions from developing countries are now
emerging as possible centres of excellence in specific aspects of the
drug discovery process. Examples include the National Institute
for Parasitic Diseases in Shanghai supporting screens for
schistosomiasis, the BIOTEC Institute in Bangkok supporting
TB and malaria screens and chemistry, the University of Cape
Town for malaria, and the National Institute for Pharmaceutical
Research and Development in Abuja, Nigeria, for TB and
malaria.
During the past 4 years, the TDR drug discovery programme
has evolved from simply performing compound screening to an
www.plosntds.org 2 August 2009 | Volume 3 | Issue 8 | e440integrated virtual drug discovery network that includes other parts
of the discovery process, including target selection, medicinal
chemistry, and DMPK activities, with the goal of identifying lead
and drug candidates to sustain and feed the development pipelines.
This network differs from other drug discovery initiatives by way
of its broad disease scope, its distributed and virtual nature, its
central coordination or management approach, the potential for
spin-off of independent initiatives, and above all, the North–South
and South–South capacity-building elements [1,27]. These factors
also illustrate the significant economies of scale achieved through
the networks. The network activities have further evolved to
include specific hit-to-lead as well as lead optimization projects
driven by designated project teams within the larger network.
Despite the progress being made by several agencies, including
through PPPs as well as dedicated academic and industry
activities, critical ‘‘translational innovation’’ gaps still remain (from
screening for hits to lead identification and optimization) for all of
these diseases (Figure 1). This analysis is based on the number of
ongoing projects at each stage of the discovery and development
process from the various PPPs involved in portfolio management
and other organizations. Our data is consistent with an earlier
analysis that led to the inclusion of lead discovery as a strategic
area of work in the new TDR strategy (see [38]). The present study
mimics the findings by the BIO Ventures for Global Health [26];
however, the disease scope in our study is broader and includes the
activities of the North–South drug discovery network implemented
by TDR.
The encouraging progress achieved through the innovative
North–South drug discovery network has raised the interesting
possibility for the emergence of independent initiatives from the
network. Examples of such initiatives include the Helminth Drug
Initiative and the African Network for Drugs and Diagnostics
Innovation.
The Helminth Drug Initiative (HDI) was initiated in 2006
following recommendations from expert consultative meetings
convened by TDR. An HDI Task Force has been established to
support the implementation of agreed activities [39,40]. The initial
mission of HDI is to discover preclinical drug candidates for
further development against schistosomiasis, onchocerciasis, and
lymphatic filariasis. A major challenge in the search for new drugs
targeting helminth diseases is the lack of robust in vitro biological
test systems with a suitable sample throughput, i.e., .10,000
compounds per annum, as well as a lack of validated targets to
support high-throughput screening (HTS) [39]. Unlike other
neglected diseases such as malaria, and diseases caused by
kinetoplastid parasites, there is no dedicated product development
partnership focusing on helminth diseases.
A critical mass of competent investigators and R&D infrastruc-
ture exists in some developing countries, including countries in
Africa. With additional new capacity being built by several
agencies, more trained investigators will become available in the
coming years [1,41]. In the past 2 years, several postdoctoral
fellows from developing countries have been trained in industry or
academia located in both the North and South as part of the drug
discovery network activities. Furthermore, ongoing collaborations
with MerckSerono, Pfizer, and other network partners from the
public sector are all contributing to this capacity building [1,42].
The medicinal chemistry centre at the University of Cape Town,
as well as the screening centres at the Theodor Bilharz Research
Institute (TBRI) in Cairo and other institutions, have made
Figure 1. Attrition rates and current drug R&D pipeline for neglected diseases. The early-stage drug pipeline for neglected tropical
diseases when compared with a typical industry-driven pipeline for diseases with commercially attractive indications illustrates a significant gap in
the discovery and preclinical phases, referred to as ‘‘translational innovation gap’’. Our current analysis is consistent with earlier reports [1,25].
Assuming that the average industry attrition rates apply to projects in neglected diseases, the current screening, lead identification, and optimization
programmes are significantly below what is required to yield a registered drug. This insufficiency leads to a ‘‘translational innovation gap’’ that needs
to be urgently addressed to ensure the availability of new drugs for neglected diseases. (Sources: TDR, MMV, TB Alliance, and a number of academic
institutions.)
doi:10.1371/journal.pntd.0000440.g001
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network activities. The University of Cape Town has progressed a
hit-to-lead project into full lead optimization through the
dedicated work of African scientists including in vitro absorption,
distribution, metabolism, and excretion (ADME) support from the
African Institute for Biomedical Science and Technology (AiBST)
in Harare, Zimbabwe. The TBRI, the Kenya Medical Research
Institute (KEMRI), and the National Institute for Pharmaceutical
Research and Development (NIPRD) in Abuja, to mention a few,
have screened thousands of small molecules and natural products
against schistosomiasis, malaria, and tuberculosis with several hits
identified. These successes have provided the impetus for the
establishment of the African Network for Drugs and Diagnostics
Innovation (ANDI) with the objective of promoting and sustaining
an African-led R&D innovation platform by discovering, devel-
oping, and delivering new products for diseases that are
predominant in Africa [43]. ANDI is also envisioned to support
capacity building and research on traditional medicines through its
activities. A strategic and business plan is now being developed as
part of the mandate of the ANDI task force that was established
following the inaugural meeting in Abuja in October 2008. The
future plan is to extend similar innovation networks to Asia and
South America. We believe that such regional networks could
become self-sustaining in the medium to the long term and can
contribute to socioeconomic development in the respective
regions.
With the expansion and success of the TDR drug discovery
network, several new challenges have become evident. In
addition to managerial and financial challenges, compound
progression is sometimes delayed due to the slow turnaround
time of screening or DMPK data that are required to guide
synthesis efforts and specific lead optimization activities. Mech-
anisms are continually being put in place within the network to
overcome these challenges. These challenges and emerging
opportunities within the respective networks are discussed in
the following paragraphs.
Drug Target Prioritization Network and Rational Drug
Design
De novo discovery of new chemical entities, starting with target
selection, validation, and HTS (real or virtual) against molecular
targets in protein-based assays, has received a lot of attention in
the past few decades, especially with its link to genomics [44–48].
The goal of such campaigns is to identify ‘‘hits’’ with defined
modes of action for further assessment in whole parasite assays and
in vivo disease models. Unfortunately, the results achieved to date
through this approach in the area of antibacterials and
antiparasitics have been minimal due to high attrition [1,49,50].
Hits emerging from recent target-based HTS campaigns at various
public and private institutions (for example, a TDR-supported
screen at the Walter and Eliza Hall Institute [WEHI] in
Melbourne) have largely not shown good correlation between
enzyme inhibition and whole cell activity [51]. The WEHI screen
was performed with about 100,000 compounds against the
following enzymes: Trypanosoma cruzi trypanothione reductase,
Trypanosoma brucei farnesyl pyrophosphate synthase, Plasmodium
falciparum pyrophosphokinase, and histone deacetylase [1,36].
DNDi is taking some of the hits that emerged from the screens
forward.
It must be emphasized that the validation status of most of the
enzymes or proteins used for these screens is not clear.
Understandably, the genetic validation tools available for some
of the parasites is limited or even nonexistent, and chemical
validation is yet to be implemented widely. It should be recognized
that neglected diseases are only beginning to benefit from various
HTS technologies implemented in the pharmaceutical industry for
commercially attractive indications a few decades ago [27,44,46].
What is needed now is a collective effort to exploit the initial
investment made by the international community in sequencing
the genomes of the various parasites in the discovery of new
treatments [52–57]. This has led to the establishment of the TDR
Drug Target Prioritization Network, which has developed an
open-source database of drug targets [58] covering multiple
disease pathogens in support of target selection for rationale drug
design [59]. This database could support the development of
innovative in silico screening tools for infectious tropical diseases,
including computational and structural approaches for the
discovery of novel pharmacophores.
A recent drug discovery agreement between Novo Nordisk, the
National Centre for Drug Screening (NCDS) in Shanghai, China,
and TDR, whereby targets are selected through TDR partners
and the TDR targets database for HTS campaigns, exemplifies the
utility of the targets database [60]. This agreement also includes
the training of African scientists at NCDS.
Compound Screening Network
This network is composed of public institutions from both
developed and developing countries identified through an open
call and a competitive selection process, and funded by TDR
[1,36]. The network has promoted compound screening for
neglected diseases since the early/mid 1990s by evaluating
compounds from investigators around the world at no extra cost
to the investigators. Until recently, however, most of the active
compounds or hits identified were not followed up and in most
cases only resulted in publications with little expansion of
structure-activity relationships (SARs) [1]. The network now
includes medicinal chemistry and DMPK networks (see below).
The increasing number of compounds screened through the
network coupled with the desire to improve the turnaround time
for data necessitated the recent expansion of this network with new
centres such as the University of Washington, Seattle, United
States, for antiprotozoan screens and four other centres in
developing countries, namely, the Central Drug Research Institute
in Lucknow, India, for filarial screens; the University of Buea in
Cameroon for onchocerciasis screens; the Kenya Medical
Research Institute in Kenya for natural product–based antima-
larial screens; and the University of Sa ˜o Paulo, Brazil, for screens
against American trypanosomiasis. The SOPs used by the new
centres have been reviewed and aligned with the broader network
and new data is already emerging from these centres.
The screens implemented through the screening network range
from in vitro whole parasite screens to in vivo animal testing against
the various disease pathogens as well as cytotoxicity assays. In an
effort to better understand and harmonize the different parasite
strains used, TDR undertook an inventory of strains used within
the network. It became obvious that same parasite strains are
sometimes defined by different nomenclature in different labora-
tories and the phenotype of the strains are oftentimes not well
defined. An inventory of some available parasite strains used by
the network is presented in Table 1. This inventory may not be an
exhaustive list of available parasite strains, but it provides
clarification to the sometimes confusing nomenclature and drug
sensitivity phenotypes for strains commonly used in drug discovery
today. Hopefully this inventory will be useful for the broader
neglected diseases drug discovery community.
The screening centres communicate with each other and
share lessons, SOPs, and reagents as well as data. Depending on
need, multiple centres within the network can be engaged to
www.plosntds.org 4 August 2009 | Volume 3 | Issue 8 | e440Table 1. Some Parasite Strains Commonly Used for Compound Screening.
Target Pathogens Parasite Strains Drug Sensitivity Phenotype
Chagas disease
Trypanosoma cruzi Tulahuen LacZ, Clone C4
a (same as Tulahuen ß-gal;
Tulahuen CL2; Tulahuen C4 LacZ; MHOM/CL/100/Tulahuen)
Sensitive to benznidazole, nifurtimox
HAT
Trypanosoma brucei brucei Squib427 (=STIB795)
a Sensitive to suramin; reference drugs: melarsoprol, pentamidine
STIB950
b Sensitive to melarsoprol, pentamidine and suramin; resistant to
diminazene, isometamidium and quinapyramine
GUTat3.1
b Sensitive to suramin; reference drugs: melarsoprol, pentamidine
STIB345
a Sensitive to diminazene aceturate
Trypanosoma brucei gambiense STIB754/130R
a Sensitive to melarsoprol, pentamidine and suramin
STIB930
b Sensitive to melarsoprol, pentamidine and suramin
Trypanosoma brucei rhodesiense STIB900
a Sensitive to melarsoprol, pentamidine and suramin
Trypanosoma congolense STIB910 (=STIB249)
b Sensitive to melarsoprol, pentamidine and suramin
Leishmaniasis
Leishmania donovani MHOM-ET-67/L82
a (same as MHOM/ET/67/HU3; LV9) Sensitive to sodium stibogluconate and miltefosine
Leishmania infantum MHOM/MA(BE)/67
a Sensitive to sodium stibogluconate and miltefosine
Leishmania major MHOM/SA/85/JISH118
a Reference drug: sodium stibogluconate
MHOM/SU/59/NEAL-P Reference drug: sodium stibogluconate
Leishmania mexicana MHOM/BZ/82/Bel21
c Reference drug: pentamidine
Leishmania panamensis MHOM/PA/67/Boynton
c Reference drug: meglumine antimonate
Malaria
Plasmodium falciparum NF54
b Sensitive to all known antimalarials
3D7 (derived from NF54)
b Sensitive to all known antimalarials
K1
b Sensitive to mefloquine; resistant to chloroquine and pyrimethamine
GHA
b Sensitive to chloroquine
T23
b Resistant to chloroquine and pyrimethamine
D6
b Sensitive to chloroquine, pyrimethamine, sulfadoxine and quinine;
less sensitive to mefloquine
W2
b Sensitive to mefloquine; less sensitive to chloroquine; resistant to






b Sensitive to pyrimethamine; resistant to chloroquine and cycloguanil
TM90C2b






c Sensitive to chloroquine and artemisinin
N
c Sensitive to chloroquine
Plasmodium yoelii NS
c Resistant to chloroquine
Plasmodium chabaudi AS
c Resistant to pyrimethamine
Plasmodium vinckei Not known
c Sensitive to chloroquine
Lymphatic filariasis
Brugia malayi India
a Reference drug: diethylcarbamazine
Brugia pahangi Not known Reference drug: diethylcarbamazine
Onchocerciasis
Onchocerca gutturosa Ghana
a Reference drugs: amocarzine, ivermectin and melarsomine
dihydrochloride
Onchocerca lienalis UK
a Reference drugs: amocarzine, ivermectin and melarsomine
dihydrochloride
Onchocerca ochengi Cameroon
b Reference drugs: amocarzine, ivermectin and melarsomine
dihydrochloride
Schistosomiasis
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This practice avoids over reliance on one centre and also gives
the additional advantage of enabling cross validation of data
within the compound screening network. A potential disadvan-
tage is the possibility to create redundancy and undue
competition within the network. However, these concerns have
not in any way hindered progress within the network. A central
facility for compound management and databases help to
overcome some of these challenges including communications
within the network.
Compounds are sourced by TDR and distributed to the
respective centres from a central compound management facility.
The decision as to which compounds are to be screened by any of
the centres is made by TDR. This decision is made with due
consideration to ongoing screens, available capacity at a particular
centre, and the type of compounds available for distribution. For
instance, compounds with some animal health rationale are
initially dispatched for anthelminthic screens. Once the in vitro
screens are completed, the next challenge becomes the analysis
and prioritization of actives especially for a large compound
collection. This time-consuming prioritization of hits is perhaps
one of the current bottlenecks for screens for neglected diseases—it
includes closer assessment of chemical structures and drug likeness
of all the hits before reaching a decision on further evaluation. For
the North–South network, this task is implemented with the help
of experienced consultants with industry experience recruited by
TDR.
An analysis of the compound screening throughput at the
various centres shows that approximately 10,000 compounds
were evaluated against whole parasites in 2004–2005 compared
with over 30,000 compounds in 2006–2007. This significant
increase in the number of compounds reflects the substantial
compound availability through TDR and its partners, including
Pfizer, Chemtura, MerckSerono, and others. This has also
resulted in some screening centres reaching their maximum
capacity for the past 2 years. In addition, several hundred of the
in vitro hits resulting from the ongoing prioritization exercise
have been evaluated in in vivo animal tests and potential leads
are continually being evaluated and considered for further
optimization. To be clear, the compound screening network is
primarily involved in in vitro (low to medium throughput) cell-
based screens as well as in vivo animal parasite screens, and not
the high-throughput target-based screens discussed earlier.
However, the network is continually seeking funding opportu-
nities to improve the throughput of available assays for tropical
diseases.
Medicinal Chemistry Network
The medicinal chemistry network was established by TDR in
2005 with the objective to take forward the hits emerging from
the screening activities through individual hit-to-lead and lead
optimization projects. This network includes public institutes and
pharmaceutical companies from developed and developing
countries selected through a competitive call for applications.
The present membership of this network includes the University
of Cape Town, South Africa; University of Dundee, United
Kingdom; University of Nebraska, US; Ohio State University,
U S ;S t .J u d eH o s p i t a l ,M e m p h i s ,U S ;P f i z e r ,M e r c k S e r o n o ,
Chemtura, and Pharmacopeia. A recent addition to the network
is the University of Sa ˜o Paulo, Brazil, which is now working on a
hit-to-lead project for compounds that are active against
Trypanosoma cruzi, the pathogen that causes Chagas disease. As
part of the capacity-strengthening component, a local in vitro/in
vivo screening centre has been identified to support this project
and two local postdoctoral trainees have started working on the
project.
A variety of screening hits from different sources—industry,
academia, and commercial suppliers—can enter the hit-to-lead
and lead optimization process through the medicinal chemistry
network once appropriate contractual agreements (materials
transfer or technical services agreements) are reached with the
respective centres. Issues contained in the agreement range from
ownership/intellectual property rights on compounds, ana-
logues, and data generated for infectious tropical diseases to
the need for publications. The initial phase of the agreement
typically focuses on lead or drug candidate discovery, with the
understanding that if the results of the work provide reasonable
indications that one or more of the compounds may be useful in
the treatment of any of the diseases of interest, then the parties
will enter another agreement on the further development of the
compound(s) and to make the product available to the public,
especially the public sector of developing countries, under
preferential pricing.
A challenge that is emerging with select public institutions
within the medicinal chemistry network is the tendency for some of
these centres to over-value their contributions even when they are
aware that the compounds they are working on and the original
ideas behind the project, including funding, are not entirely
coming from their institutions. This stems from the desire by these
partners to have full ownership of intellectual property and control
all results without consideration for the contribution of colleagues
from other parts of the network, but most importantly without due
consideration to the need for future identification of downstream
development partner(s) if the compound survives the harsh
attrition in the discovery phase. Resolving this issue is not always
simple but obviously requires a strong leadership to ensure that the
participation of different parties in the network is primarily driven
by public health outcomes.
A select example of data from commercially available
compounds acquired by TDR that formed the bases for the
Target Pathogens Parasite Strains Drug Sensitivity Phenotype
Schistosoma mansoni Puerto Rican
a Reference drug: praziquantel
Egyptian Sambon
a Reference drug: praziquantel
Schistosoma haematobium Egyptian
a Reference drug: praziquantel
aUsed for both vitro screens and vivo rodent models.
bUsed for vitro screens.
cUsed for vivo rodent models.
doi:10.1371/journal.pntd.0000440.t001
Table 1. Cont.
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below.
TDR 17516—Hit-to-Lead Project for Malaria
A screening campaign commissioned by TDR at Tibotec using
17,472 non-proprietary compounds sourced from SPECS resulted
in the identification and confirmation of the antimalarial activity of
a compound subsequently coded TDR 17516 (Figure 2).
The resulting data include in vitro IC50s (ug/ml) against the
following P. falciparum strains: K1 0.03 (compared with chloro-
quine 0.02) Selectivity Index (SI).3000; NF54 0.0044 (compared
with chloroquine 0.004); D6 0.0158 (compared with chloroquine
0.004); W2 0.058 (compared with chloroquine 0.084); TM91C235
0.049 (compared with chloroquine 0.046); and TM90C2B 0.082
(compared with chloroquine 0.08).
The in vivo data with mice infected with P. berghei include 97.7%
inhibition of parasitemia at 46100 mg/kg via the intraperitoneal
(ip) route of administration; 91.3% inhibition at 3650 mg/kg via
ip route with 11 mean survival days (MSD) (#7 MSD for control),
and inactive at 1630 mg/kg ip. Although further amounts of
TDR17516 could not be sourced, it was possible to acquire 12
analogues to develop some SARs. Thus, moving the methoxy
group from the 5 position (TDR 17516) to the 7 position (TDR
42098; Figure 2) allowed activity to be retained against P.
falciparum K1 (IC50 0.03 ug/ml). However, moving it to 6 position
(TDR 42099) results in a 10-fold loss of activity against the P.
falciparum strain, whilst relocating it to the 8 position (TDR 42102)
abolishes activity. Likewise, introducing alkyl substituents onto the
N atom also resulted in loss of activity. Assessment of TDR 42098
in P. berghei–infected mice at 4650 mg/kg ip showed no activity
but no further material was available at the time. Additional
analogues were needed to develop SARs further, plus more
TDR17516 to complete assessment of efficacy in mice and to
obtain a pharmacokinetic (PK) profile. A literature search failed to
reveal published information on the lead (TDR17516), although
the synthesis of numerous analogues have been reported but
without claims of antimalarial activity. This series was assigned to
the St. Jude Children’s Hospital in Memphis for further chemistry
in 2006 by TDR. In addition to the project idea and supporting
data, TDR also provided funding support and consultant as well as
ADME support through the Monash University in Australia and
AiBST. It should be mentioned that the Swiss Tropical Institute
generated additional biological data in support of the series
transferred to St. Jude’s.
TDR 22093—Hit-to-Lead Project for Malaria
In an HTS campaign commissioned by TDR at Discovery
Technologies Ltd., a non-proprietary compound library of 19,000
samples was screened against a plasmodial calcium-dependent
protein kinase (Pf CDPK1). This resulted in a small number of hits
(IC50 1–10 uM) that were then tested against P. falciparum,
culminating in the identification of one compound of interest, AE-
848/08643022 (ex-SPECS), with moderate activity against the
enzyme and whole parasite—approximately IC50 2.88 uM. A
search for related compounds was then made within the SPECS
database and 38 analogues were subsequently sourced and tested
againstbothenzymeandparasite.Althoughtheenzymeactivitywas
moderate with no compound having an IC50,10 uM, only one
compound, AE-848/08581029, now called TDR 22093 (Figure 2),
showed excellent activity against the P. falciparum K1 strain.
The in vitro P. falciparum IC50 (ug/ml) against K1 (Table 1) was
0.016 compared to chloroquine at IC50 0.03 and SI,400. The
compound was also active against the NF54 strain.
Critical issues with the series included the need to synthesize
further amounts of TDR 22093 to allow oral assessment against
P. berghei a n dt od e t e r m i n eA D M Ep r o f i l e ,a n du n d e r s t a n dt h e
SAR. In a search of the chemical literature, TDR 22093 was not
found, although synthetic routes to close analogues such as CAS
74944-18-6 (Figure 2) were readily synthetically accessible (see
structure above). This series was assigned to Pharmacopeia in the
US for further medicinal chemistry and initial metabolism
profiling in 2006 with initial funding from TDR. In 2007,
MMV became a funding partner on the project, and this
additional support helped to reach a ‘‘no-go’’ decision on this
project within a year.
TDR20364—Hit to Lead Project for Human African
Trypanosomiasis
The same non proprietary compounds sourced from SPECS
were tested against Trypanosoma brucei at Tibotec. From this initial
assessment, TDR 15949 was identified with reasonable activity
against T. b. brucei (IC50,0.5 uM). This compound contained the
undesirable dinitrophenyl group, and subsequently a further 14
non-nitro analogues were sourced from SPECS and screened
again. The data revealed only one compound, TDR 20364
(Figure 2), with significant activity in the Tibotec T. b. brucei assay.
(Note: T. b. brucei is a cattle parasite used in the primary in vitro
assay at Tibotec and in the primary in vivo screen at STI; in the
latter it is coded as STIB 795 and is used because it is not
refractory to treatment as STIB 900 is in mice.)
Figure 2. TDR17516 and analogue TDR42098; TDR 22093 and
analogue CAS 74944-18-6; and TDR 20364.
doi:10.1371/journal.pntd.0000440.g002
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against T. b. rhodesiensegave even more encouraging activity with an
IC50 0.034 ug/ml. (Note: T. b. rhodesiense is a human parasite used in
the primary in vitro screen at the STI and in the secondary in vivo
assayinmice[straincoded STIB900,curesaredifficulttoachieve].)
No further stocks of TDR 20364 were available for in vivo
animal testing. However, a further 187 analogues were sourced
from PrincetonBio of which 38 had IC50,0.05 ug/ml against
T. b. rhodesiense. Many of these were simple ester variants of the
lead compound. Two analogues, TDR 44218 (IC50 0.0075 ug/
ml) and 44219 (0.038 ug/ml), were potent against the parasite
and lacked the potential metabolic liability of an ester group. In
vivo assessment in mice at 4650 mg/kg ip against T. brucei STIB
795 showed an encouraging prolongation of life despite
parasitaemia reduction being minimal with MSD.23.75 for
TDR 44218 and 15.5 for TDR 44219, compared to 6.25 for
control. Investigation of SARs showed that the majority of these
compounds were close analogues of TDR 20364 with similar
generic structure.
This series and analogues tested were assigned to Ohio State
University for further chemistry in 2006. In addition to the
project idea, TDR provided funding, medicinal chemistry
consulting, and biology screening at the Swiss Tropical Institute
and University of Antwerp, as well as ADME support through
Monash University and AiBST. These network partners work
collaboratively. A further SAR has been developed through this
iterative medicinal chemistry work, and the project is now in lead
optimization.
Drug Metabolism and Pharmacokinetics Network
There is an increasing realization within the neglected diseases
drug discovery community that early integration of DMPK in the
drug discovery process is critical. Until recently, most drug
discovery efforts for neglected diseases, especially those based in
academic institutions, have focused on the synthesis of compounds
with little guidance from parasite screening and DMPK data (in
vitro and in vivo). This is understandable given that most academic
laboratories have limited resources for carrying out advanced
preclinical drug development.
Identification of quality leads requires extensive in vitro and a
degree of in vivo ADME assessment aimed at guiding optimal
chemical synthesis and SAR exploration (Box 2). The initial
challenge in integrating DMPK into the drug discovery network
was the identification of centres with the relevant capability. It
was relatively easy to identify industrial partners already
collaborating with TDR on compound supply and medicinal
chemistry such as Pfizer, MerckSerono, Pharmacopeia, and
Chemtura since a strong in-house capability for DMPK already
exists within these companies. Interestingly, some of these
companies have DMPK and toxicology data for some of the
compounds supplied for screening. To be able to evaluate
compounds from academic medicinal chemistry partners
working on TDR compounds, the Monash University in
Melbourne, Australia, and the AiBST, Zimbabwe, were
identified. These two institutions have good track records and
are already making excellent contributions to the activities of
the entire network. However, with the increasing number of hit-
to-lead projects within the medicinal chemistry network, it has
become necessary to scale up the DMPK network with
additional centres and resources to ensure the rapid turnaround
of data to guide chemical synthesis.
A new development is that several external groups with hits
or leads are now approaching TDR for DMPK support for
their projects in a manner similar to support provided for
compound screening over the years. Unfortunately, TDR has
not been able to provide significant experimental DMPK
support to projects that are external to the network due to
limited resources. There is the possibility of using contract
research organizations for early DMPK work, but issues like
costs associated with repeated profiling of compounds, choice of
initial assays, and continuity makes this option unattractive for some
investigators.
Network Coordination and Interface with Other
Organizations
The success of any collaborative R&D effort largely depends
on the management as well as the support available for the day-
to-day implementation of the activities. The close interaction
and interface between the individual networks is crucial in this
regard. A regular joint meeting of the screening, medicinal
chemistry, and DMPK networks has been implemented to help
foster this close interaction, the sharing of data, and open
discussion of issues relevant to all parties. In addition, individual
hit-to-lead or lead optimization teams meet to discuss and
address specific project needs within the network. An Expert
Drug Discovery Advisory Committee (EDAC) also provides
strategic review of the network projects annually. EDAC is
composed of external experts from developing and developed
countries with experience in the various areas of drug discovery,
product development, public health, and parasitology. The
EDAC review is based on a set of criteria for each of the
networks. For example, the criteria for review of the screening
centres include progress towards agreed milestones, the number
of compounds screened and reproducibility of data, and the
turnaround time of compound screens and data, as well as close
interaction with chemistry and DMPK centres. The ideal turn
around time is 4 weeks for in vitro s c r e e n sa n d2m o n t h sf o rin
vivo. Similar criteria for medicinal chemistry, DMPK, and the
targets network are also available. During the annual review,
decisions are made about funding renewal for the individual
projects; projects or centres that do not meet the expectation of
the network are dropped. A recent review of the program by
EDAC identified the need to strengthen the toxicological
evaluation of promising compounds.
Due to the limited number of available experts in product R&D
for neglected diseases, the network and indeed other R&D
institutions are sometimes faced with the challenging task of
identifying committee members. Committee members may
sometimes have personal or institutional interests in projects or
ideas being reviewed and evaluated. This potential conflict of
interest is recognized and managed proactively. Participants at all
meetings organized by WHO are asked to declare and sign a
conflict of interest statement.
The North–South network model is not a panacea. A major
part of the network coordination efforts is to ensure synergy and
appropriate interface with other product discovery and devel-
opment efforts for optimal impact. For example, the drug
discovery centres at the University of California in San
Francisco, the University of Dundee, the Swiss Tropical
Institute, and the University of Antwerp, as well as institutions
in the South such as University of Cape Town, the National
Institute of Pharmaceutical Research in Abuja, Nigeria, and the
Central Drug Research Institute in Lucknow, India, are all
performing independent drug discovery research while also
contributing to the drug discovery network activities. Some of
the PPPs are also participating on specific hit-to-lead or lead
optimization projects that have emerged from the network
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antimalarial lead discovery projects, while DNDi is working
with the TDR network on some hit-to-lead projects for Chagas
disease. Several biopharmaceutical, animal health, and specialty
chemical companies, such as Pfizer, MerckSerono, Novo
Nordisk, Bayer, Pharmacopeia, Scynexis, Chemtura, and
Syngenta, are supporting the network in different capacities
[1]. Some pharmaceutical companies have established dedicated
drug discovery units for specific target diseases; for example, the
GSK facility in Tres Cantos, Spain, focusing on malaria and TB,
the Novartis Institute in Singapore focusing on TB, malaria, and
dengue, and AstraZeneca in Bangalore and Eli Lilly in Seattle
focusing on TB. These independent efforts are also encouraged
to tap into parts of the network, for example, the TDR Target
Database is an open-source database supporting global target
selection which some of these initiatives are utilizing. Lessons
learned through the screening network are broadly communi-
cated for the benefit of other initiatives. Having said this, it
should be emphasized that the pre-competitive but more open
innovative nature of the North–South discovery network, as well
as the disease scope, distinguishes this model from some of the
other drug discovery initiatives. Although the present focus of
this activity is lead and candidate discovery, it should be
emphasized that strategies are being established to ensure that
resulting drug candidates are promptly taken forward into
development. One mechanism is to hand off leads to partners
with the capacity for further optimization or development of
such leads under appropriate contractual agreement, for
example with PPPs or industry. Another mechanism supported
by TDR that focuses on promoting innovation for product
development in developing countries is now emerging as a viable
option for hand off of leads or drug candidates to suitable centres
or partnerships in developing countries. This latter approach is
being strengthened through the establishment of regional
networks exemplified by ANDI, as described earlier.
Hit-to-Lead and Candidate Criteria
Current progress within the drug discovery network was, in
part, made possible through the establishment of clear hit-to-lead
and lead-to-drug candidate progression criteria covering the drug
discovery process (Boxes 1 and 2). These progression criteria cover
biological, physico-chemical, and pharmacokinetics, as well as
early safety and toxicological components of drug discovery for
various neglected diseases including malaria, African trypanoso-
miasis, Chagas diseases, leishmaniasis, lymphatic filariasis, oncho-
cerciasis, and schistosomiasis [1,3,36,46,61]. The goal of present-
ing these criteria is to share our experience with various groups
involved in drug discovery for neglected diseases with regards to
the type of data required for compound progression and drug
candidate selection. These criteria are not a substitute for specific
target product profiles for each disease [1,3], but rather it should
complement the target product profiles as decisions are reached on
compounds to progress into clinical development.
Future Perspectives
Some may believe that promoting capacity building as an
integral component of the product R&D process can distract from
achieving the ultimate goal of discovering and developing drugs in
a timely manner. We argue the contrary. Data now emerging from
the North–South and South–South drug discovery networks show
that human and institutional capacity can be built around drug
discovery projects with clear product milestones and deliverables.
Some of the medicinal chemistry, screening, and DMPK activities
supported by young postdoctoral trainees in developed and
developing countries have generated quality lead candidates. A
recent example is the TDR 15087 hit-to-lead project for malaria at
the University of Cape Town, which has progressed to lead
optimization activities within 2 years. Although this project is
supported by other TDR networks, most of the chemical synthesis
has been performed by postdoctoral fellows from Africa, some of
whom have already completed their training and have returned to
their respective home institutions to start similar drug discovery
projects. We believe that this trend will contribute to long term
sustainability of access to essential medicines in disease-endemic
countries.
The scalability of the network model can take the form of
expansion of ongoing activities or spinning off parts of the activities
depending on need or extending the model to other indications,
including orphan diseases that occur in developed countries as well
as the more commercially attractive indications. The more open
innovation through the network does not threaten the creation or
ownership of intellectual property [26], but rather may set the
stage for an easy, cost-effective and more public health–centred
approach for the discovery of novel medicines for various diseases,
including antibacterials, antidiarrhoeals, and antiviral agents. The
establishment of the African Network for Drugs and Diagnostics
Innovation, whose objective is to promote and sustain African-led
product R&D activities, is an example of a new initiative that can
take on this challenge in Africa. We believe that stronger
participation of the disease-endemic countries in the discovery,
development, and delivery of the products they need will
significantly contribute to ensuring long-term sustainability leading
to the availability of health products for those countries. This
emerging trend of promoting participation of developing countries
in the innovation process needs broad support locally and
internationally.
The innovation network activities described here are relevant
to the WHO global strategy and plan of action on public health,
innovation, and intellectual property [62]. This network covers
parts of the eight elements of the global strategy and plan of
action, which include: 1) prioritizing research and development
needs, 2) promoting research and development, 3) building and
improving innovative capacity, 4) transfer of technology, 5)
management of intellectual property, 6) improving delivery and
access, 7) ensuring sustainable financing mechanisms, and 8)
establishing monitoring and reporting systems. Other existing
mechanisms, such as PPPs exemplified by MMV, the Global
Alliance for Vaccines and Immunisation, the International
AIDS Vaccine Initiative, Foundation for Innovative New
Diagnostics, the Global Alliance for TB Drug Development,
and DNDi, should also be supported. Recent calls for
applications announced by the Bill & Melinda Gates Grand
Challenges [24], the Wellcome Trust [25], and some govern-
ment agencies demonstrate the increasing appreciation that
investment in R&D, capacity, and institutional development in
disease-endemic countries will help to ensure sustainability in
the longer term [1,63]. We believe that equitable access and
longer term availability of health products will be realized if we
invest and promote R&D, and manufacturing within those
countries.
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For clarity, a ‘‘hit’’ is a compound with selective in vitro
activity (usually IC50,1 mM or expressed as ug/ml or
appropriate unit) against whole parasite or enzyme or
receptor, while a ‘‘lead’’ is a compound with basic drug
characteristics conforming with the target product profile of
a disease based on initial in vitro and animal data including
efficacy, ADME, cytotoxicity, and chemical parameters.
Progressing a hit to lead, and lead to drug candidate,
requires a set of in vitro and in vivo efficacy, in vitro and in
vivo ADME, cytotoxicity, and safety data, and physicochem-
ical characterization. The acceptable baseline data required
for lead and drug candidate declaration is summarized
below and in Box 2.
Hit-to-Lead Identification Criteria Chemistry/
Physicochemical Properties
N Chemical structure confirmed and synthetic route estab-
lished
N Good drug likeness index (e.g., #Lipinski Rule of Five
violation for small molecules, no reactive entities in the
structure)
N Compound could be reproducibly resynthesized to .90%
purity
N Compound is chemically exploitable with regard to the
potential for further SAR development and preferably
novel
N IP situation clarified with no hindrance to exploitation for
diseases of interest
N Predicted or measured physical chemical properties
including aqueous solubility and permeability to demon-
strate drug likeness for small molecules
N Indication of SAR pattern
N Natural product: structure of purified compound deter-
mined
Biological and Initial Safety Data
N In vitro activity confirmed against enzyme, protein, or
whole cells
N Antiprotozoan screens: IC50 and sensitivity index (SI)
(ratio of L-6 IC50 and parasite IC50):
N Plasmodium falciparum: ,0.2 mg/ml, SI.100
N Trypanosoma brucei rhodesiense: ,0.2 mg/ml, SI.100
N Trypanosoma cruzi: ,1.0 mg/ml, SI.50
N Leishmania donovani or L. Infantum: amastigotes in
macrophages 1–2 mg/ml, SI.20;
N Anthelminthic screens:
N Schistosoma mansoni: 100% adult worm motility
reduction, IC50,2 ug/mL
N Onchocerca lienalis or O. ochengi or O. volvulus: 100%
inhibition of microfilarial motility at 1.2561025Mo r
10 ug/ml
N Brugia malayi: 100% inhibition of microfilarial motility;
100% inhibition of adult worm motility and/or inhibition
of MTT reduction at 10 ug/mL
N Determine selectivity over other related targets/parasites
N Demonstrate correlation between enzyme and parasite
activity where the enzyme target of a compound is known
N Established selectivity for a molecular target or differential
sensitivity between parasite and host enzymes should be
.10-fold
N Active against resistant and sensitive strains (variation
between strains is a warning sign)
N Acceptable pre-toxicity screening data in cellular screen
and animals
N Cytotoxicity (selectivity index)
N Pre-toxicity screen in non infected mice using up to 100 mg/
kg ip or po before in vivo efficacy studies
N In vivo activity usually in mouse or hamster models:
significant reduction in parasitaemia and/or increase in life
span, at 4650 mg/kg either through the ip or po route
with no overt sign of toxicity
N Plasmodium berghei mouse model: .80% parasitaemia
reduction & MSD of greater than that of untreated control
(i.e., .7d a y s )
N T. b. rhodesiense mouse model: 60 d aparasitaemia
N Trypanosoma cruzi mouse model: MSD.30 days
N Leishmania infantum hamster model or L donovani mouse
model: .8 0 %r e d u c t i o ni na m a s t i g o t eb u r d e n
N S. mansoni mouse model: .75% reduction of adult worm
load at 5650 mg/kg
N Onchocerca lienalis/O. ochengi mouse model: $75%
reduction in microfilarial worm recovery at 5650 mg/kg
N Brugia malayi jird or Mastomys model: $80% reduction
in microfilaria or adult worm recovery at 5650 mg/kg
N Biological activity of single enantiomers determined if
appropriate
Metabolism
N Metabolic stability determined in microsomes in at least
two species including humans
N Preliminary exposure, ideally in the efficacy species, under
conditions relevant to efficacy testing protocol
Lead Selection Dossier
N Preparation of a complete dossier containing an updated
profile of compound and data accumulated so far
N Dossier reviewed and accepted by appropriate TDR
consultants or committee
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Lead Optimization Criteria
The goal is to develop further SARs around a lead to identify
a short list of at least three candidates based on iterative
medicinal chemistry to improve the intrinsic pharmacolog-
ical properties of a lead, including activity in appropriate
animal model, pharmacokinetics parameters, and explorato-
ry toxicological assessments. The following criteria must be
met to achieve this objective:
Project Manager Assigned:
N Work collaboratively to advance compound
N Identification of development partner and hand off
approach clarified
Chemistry/Physico-Chemical Properties
N Criteria specific for oral (po) route of administration:
aqueous solubility normally .1 mg/ml, logP,6
N Criteria specific to iv route of administration: aqueous
solubility .1 mg/mL
N IP situation of compound clarified: require freedom to
operate
N Preliminary assessment of chiral and diastereomeric purity
if appropriate
N Chemistry amenable to synthetic analoging
N Process chemistry initiated for scale-up quantities (non
GMP)
N Cost of Goods (COG) considerations highlighted
Efficacy Data (In Vitro and In Vivo Activity)
N IC50/Ki (dissociation constant for binding of inhibitor to an
enzyme) against enzyme/receptor/target useful
N Whole organism activity IC50/IC90 versus a panel of
laboratory strains—sensitive and resistant strains estimat-
ed
N Mode of action with regards to cidal or static useful to
know
N Dose-related in vivo (rodent) activity,50 mg/kg estab-
lished by proposed clinical route of administration
(preferably oral) in comparison with appropriate reference
compounds
N In vivo (rodent model) ED50/ED90 with acceptable pharma-
ceutical formulations in the predicted route for clinical
trials
N Activity in a secondary assay if needed (e.g., central
nervous system [CNS] mouse model like GVR35 strain for
second stage HAT)
N Confirmed selectivity for the pharmacological target
Metabolism
N Metabolic stability in microsomes (intrinsic clearance in
human and animal species)
N Relative ranking of potential to interact in vitro (as
substrate or inhibitor) with human cytochrome P (CYP)
2D6, 3A4
N Acceptable CYP450 inhibition data
Pharmacokinetics
N po/iv pharmacokinetics in rodent species over therapeutic
dose range may be useful
N Oral bioavailability targeted to a minimum of 20%
N Confirm in vivo systemic and/or tissue drug levels reach/
exceed in vitro potency concentration
N Plasma half-life, Cmax, clearance, and volume of distribu-
tion in rodents
Safety Pharmacology
N hERG channel binding .10 mM (or dose escalation studies)
N Testing against a panel of G-protein coupled receptor
(GPCR) and ion channel sites
Decision:
N Preparation of a complete dossier containing data
accumulated so far
N Summary of all data in matrix with a comparator drug.
Candidate Selection Criteria
The goal is to perform additional studies to aid in the
selection of a development candidate from about three or
four top candidates for good clinical practice (GLP) pre-
clinical development. Ideally, a candidate selection commit-
tee should be created to rank the candidates. In addition to
data from lead optimization, the following criteria must be
met to achieve this objective:
Chemistry/Physico-Chemical Properties
N Physical form of compound characterized log D, pKa,
solubility, stability (tropical conditions). Salt form evaluated
and most likely decided upon, and preclinical formula-
tion(s) developed for use in PD/PK (pharmacodynamic/
pharmacokinetic) determinations. COG estimate
N IP situation of compound: requires patentability
N Process chemistry initiated to scale-up to kg quantities
(non-good manufacturing practice [GMP])
N Consideration for back-up candidates as appropriate
Efficacy Data (In Vitro and In Vivo Activity)
N Confirmed selectivity for the pharmacological target
Metabolism
N Major metabolites identified and characterized
N Enzyme induction potential; if necessary, test in human
hepatocytes/suitable human cell line
N Evaluation of binding to major plasma proteins
Pharmacokinetics
N Full PK in at least three species including monitoring for
major metabolites if possible, and allometric scaling for
human dosing by the intended route of clinical adminis-
tration
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